APOE and Alzheimer disease: Our study was aimed at determining whether clinical heparin usage received prior to the diagnosis of AD is associated with a difference in age of disease diagnosis and was motivated by recent compelling genetic and molecular findings that implicate HSPGs as potential mediators of the pathogenic and protective effects of APOE genotypes upon AD.